William Blair Issues Optimistic Outlook for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities research analysts at William Blair increased their Q2 2025 earnings estimates for Neurocrine Biosciences in a report issued on Tuesday, May 6th. William Blair analyst M. Minter now anticipates that the company will earn $1.02 per share for the quarter, up from their prior estimate of $0.85. William Blair has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. William Blair also issued estimates for Neurocrine Biosciences' Q3 2025 earnings at $1.25 EPS, Q4 2025 earnings at $1.36 EPS, Q1 2026 earnings at $1.66 EPS, Q2 2026 earnings at $1.85 EPS, Q3 2026 earnings at $1.80 EPS, Q4 2026 earnings at $2.25 EPS and FY2026 earnings at $7.56 EPS.

Several other research analysts have also commented on NBIX. StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Evercore ISI decreased their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Piper Sandler reaffirmed an "overweight" rating and issued a $154.00 target price (down previously from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Finally, UBS Group upped their price target on Neurocrine Biosciences from $137.00 to $152.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $162.00.

Neurocrine Biosciences Price Performance

NBIX stock traded up $2.03 during mid-day trading on Friday, reaching $118.90. 1,060,247 shares of the company's stock were exchanged, compared to its average volume of 1,119,774. The stock's 50 day moving average is $106.44 and its 200 day moving average is $121.89. The company has a market cap of $11.77 billion, a price-to-earnings ratio of 36.14, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The business had revenue of $572.60 million during the quarter, compared to analysts' expectations of $587.06 million. During the same quarter last year, the business posted $1.20 earnings per share. The company's quarterly revenue was up 11.1% compared to the same quarter last year.

Neurocrine Biosciences announced that its board has authorized a stock buyback program on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

Insiders Place Their Bets

In other news, CFO Matt Abernethy sold 2,558 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.86, for a total transaction of $298,927.88. Following the completion of the sale, the chief financial officer now directly owns 34,775 shares in the company, valued at approximately $4,063,806.50. The trade was a 6.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director William H. Rastetter sold 30,000 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the sale, the director now directly owns 37,491 shares in the company, valued at $4,131,508.20. This trade represents a 44.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,953 shares of company stock worth $4,467,990. Company insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently modified their holdings of the company. Caprock Group LLC purchased a new position in Neurocrine Biosciences in the fourth quarter worth approximately $236,000. Charles Schwab Investment Management Inc. grew its stake in Neurocrine Biosciences by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company's stock valued at $104,089,000 after acquiring an additional 15,266 shares during the last quarter. Oakworth Capital Inc. purchased a new position in Neurocrine Biosciences in the 4th quarter valued at about $379,000. Avantax Advisory Services Inc. boosted its stake in Neurocrine Biosciences by 11.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company's stock worth $395,000 after buying an additional 297 shares during the last quarter. Finally, Synergy Asset Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter valued at approximately $996,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.